Skip to main content
SpringerLink
Log in

Interferon Therapy of Essential Thrombocythemia and Polycythemia Vera

  • Conference paper
Interferons

  • 96 Accesses

Abstract

The chronic myeloproliferative disorders are clonal diseases of the hematopoietic stem cell. Polycythemia vera (PV) is characterized by extensive trilineage bone marrow hyperplasia, whereas in essential thrombocythemia (ET), proliferation of the megakaryocytic lineage prevails. Both diseases run a relatively benign clinical course, and survival is almost normal. Morbidity and mortality result primarily from vascular complications, i.e., thromboembolism, micro circulatory disorders, and bleeding. Other symptoms include pruritus, splenomegaly, and in PV plethora, arterial hypertension, and signs of iron deficiency.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ania BJ, Suman VJ, Sobell JL, Codd MB, Silverstein MN, Melton LJ (1994) Trends in the incidence of polycythemia vera among Olmsted County, Minnesota residents, 1935–1989. Am J Hematol 47: 89–93

    PubMed  CAS  Google Scholar 

  2. Silverstein MN, Lanier AP (1971) Polycythemia vera, 1935–1969.An epidemiologic survey in Rochester, Minnesota. Mayo Clin Proc 46: 751–753

    PubMed  CAS  Google Scholar 

  3. Modan B (1965) An epidemiological study of polycythemia vera. Blood 26: 657–667

    PubMed  CAS  Google Scholar 

  4. Berglund S, Zettervall O (1992) Incidence of polycythemia vera in a defined population. Eur J Haematol 48: 20–26

    PubMed  CAS  Google Scholar 

  5. Modan B (1995) The epidemiology of polycythemia vera. In: Wasserman LR, Berk PD, Berlin NI (eds) Polycythemia vera and the myeloproliferative disorders. Saunders, Philadelphia, pp 140–146

    Google Scholar 

  6. Iland H, Laszlo J, Murphy S (1995) Essential thrombocythemia. In: Wasserman LR, Berk PD, Berlin NI (eds) Polycythemia vera and the myeloproliferative disorders. Saunders, Philadelphia, pp 292–310

    Google Scholar 

  7. Wehmeier A, Daum I, Jamin H, Schneider W (1991) Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. Ann Hematol 63: 101–106

    PubMed  CAS  Google Scholar 

  8. Berlin NI (1975) Diagnosis and classification of the polycythemias. Semin Hematol 12: 339–351

    PubMed  CAS  Google Scholar 

  9. Georgii A, Choritz H, Busche G, Kreft A, Buhr T (1995) Histopathologic der Ph1-negativen chronischen myeloproliferativen Erkrankungen. Pathologe 16: 62–69

    PubMed  CAS  Google Scholar 

  10. Peterson P, Ellis JT (1995) The bone marrow in polycythemia vera. In: Wasserman LR, Berk PD, Berlin NI (eds) Polycythemia vera and the myeloproliferative disorders. Saunders, Philadelphia, pp 31–53

    Google Scholar 

  11. Najean Y, Schlageter M-H, Toubert M-E, Podgorniak M-P (1990) Radioimmunoassay of immuno-reactive erythropoietin as a clinical tool for the classification of polycythemias. Nouv Rev Fr Hematol 32: 237–240

    PubMed  CAS  Google Scholar 

  12. Birgegård G, Wide L (1992) Serum erythropoietin in the diagnosis of polycythemia and after phlebotomy treatment. Br J Haematol 81: 603–606

    PubMed  Google Scholar 

  13. Casadevall N (1994) Determination of serum erythropoietin. Its value in the differential diagnosis of polycythemias. Nouv Rev Fr Hematol 36: 173–176

    PubMed  CAS  Google Scholar 

  14. Swolin B, Weinfeld A, Westin J (1988) A prospective long-term cytogenetic study in polycythemia vera in relation to treatment and clinical course. Blood 72: 386–395

    PubMed  CAS  Google Scholar 

  15. Pierre RV, Whang-Peng J (1995) Cytogenetics. In: Wasserman LR, Berk PD, Berlin NI (eds) Polycythemia vera and the myeloproliferative disorders. Saunders, Philadelphia, pp 91–101

    Google Scholar 

  16. Tanzer J (1994) Clonality and karyotype studies in polycythemia vera. Nouv Rev Fr Hematol 36: 167–172

    PubMed  CAS  Google Scholar 

  17. Partanen S, Juvonen E, Ikkala E, Ruutu T (1989) Spontaneous erythroid colony formation in the differential diagnosis of erythrocytosis. Eur J Haematol 42: 327–330

    PubMed  CAS  Google Scholar 

  18. Westwood N, Dudley JM, Sawyer B, Messinezy M, Pearson TC (1993) Primary polycythaemia: diagnosis by non-conventional positive criteria. Eur J Haematol 51: 228–232

    PubMed  CAS  Google Scholar 

  19. Fisher MJ, Prchal JF, Prchal JT, D’Andrea AD (1994) Anti-erythropoietin (EPO) receptor monoclonal antibodies distinguish EPO-dependent and EPO-independent erythroid progenitors in polycythemia vera. Blood 84: 1982–1991

    PubMed  CAS  Google Scholar 

  20. Dai CH, Krantz SB, Green WF, Gilbert HS (1994) Polycythaemia vera. III. Burst-forming units-erythroid (BFU-E) response to stem cell factor and c-kit receptor expression. Br J Haematol 86: 12–21

    PubMed  CAS  Google Scholar 

  21. Tefferi A, Hoagland HC (1994) Issues in the diagnosis and management of essential thrombocythemia. Mayo Clin Proc 69: 651–655

    PubMed  CAS  Google Scholar 

  22. Buss DH, Cashell AW, O’Connor ML, Richards F, Case LD (1994) Occurrence, etiology, and clinical significance of extreme thrombocytosis: a study of 280 cases. Am J Med 96: 247–253

    PubMed  CAS  Google Scholar 

  23. Murphy S, Iland H, Rosenthal D, Laszlo J (1986) Essential thrombocythemia: an interim report from the Polycythemia Vera Study Group. Semin Hematol 23: 177–182

    PubMed  CAS  Google Scholar 

  24. Hollen CW, Henthorn J, Koziol JA, Burstein SA (1991) Elevated serum interleukin-6 levels in patients with reactive thrombocytosis. Br J Haematol 79: 286–290

    PubMed  CAS  Google Scholar 

  25. Tefferi A, Ho TC, Ahmann GJ, Katzmann JA, Greipp PR (1994) Plasma interleukin-6 and C-reactive protein levels in reactive versus clonal thrombocytosis. Am J Med 97: 374–378

    PubMed  CAS  Google Scholar 

  26. Rolovic Z, Basara N, Gotic M, Sefer D, Bogdanovic A (1995) The determination of spontaneous megakaryocyte colony formation is an unequivocal test for discrimination between essential throm bocythaemia and reactive thrombocytosis. Br J Haematol 90: 326–331

    PubMed  CAS  Google Scholar 

  27. Juvonen E, Ikkala E, Oksanen K, Ruutu T (1993) Megakaryocyte and erythroid colony formation in essential thrombocythemia and reactive thrombocytosis: diagnostic value and correlation to complications. Br J Haematol 83: 192–197

    PubMed  CAS  Google Scholar 

  28. Thiele J, Schneider G, Hoeppner B, Wienholt S, Zankovich R, Fischer R (1988) Histomorphometry of bone marrow biopsies in chronic myeloproliferative disorders with associated thrombocytosis features of significance for the diagnosis of primary (essential) thrombocythaemia. Virchows Arch (A) 413: 407–417

    CAS  Google Scholar 

  29. Berk PD, Goldberg JD, Silverstein MN et al (1981) Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med 304: 441–447

    PubMed  CAS  Google Scholar 

  30. Higuchi T, Okada S, Mori H, Niikura H, Omine M, Terada H (1995) Leukemic transformation of polycythemia vera and essential thrombocythemia possibly associated with an alkylating agent. Cancer 75: 471–477

    PubMed  CAS  Google Scholar 

  31. Kaplan ME, Mack K, Goldberg JD, Donovan PB, Berk PD, Wasserman LE (1986) Long-term management of polycythemia vera with hydroxyurea: a progress report. Semin Hematol 23: 167–171

    PubMed  CAS  Google Scholar 

  32. Landaw SA (1995) Acute leukemia in polycythemia vera. In: Wasserman LR, Berk PD, Berlin NI (eds) Polycythemia vera and the myeloproliferative disorders. Saunders, Philadelphia, pp 154–165

    Google Scholar 

  33. Weinfeld A, Swolin B, Westin J (1994) Acute leukaemia after hydroxyurea therapy in polycythaemia vera and allied disorders: prospective study of efficacy and leukaemogenicity with therapeutic implications. Eur J Haematol 52: 134–139

    PubMed  CAS  Google Scholar 

  34. Najean Y, Dresch C, Rain JD (1994) The very-long-term course of polycythaemia: a complement to the previously published data of the Polycythaemia Vera Study Group. Br J Haematol 86: 233–235

    PubMed  CAS  Google Scholar 

  35. Löfvenberg E, Wahlin A (1988) Management of polycythemia vera, essential thrombocythemia and myelofibrosis with hydroxyurea. Eur J Hematol 41: 375–381

    Google Scholar 

  36. Rozman C, Giralt M, Feliu E, Rubio D, Cortes M (1991) Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer 67: 2658–2663

    PubMed  CAS  Google Scholar 

  37. Cortelazzo S, Finazzi G, Ruggeri M et al (1995) Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 332: 1132–1136

    PubMed  CAS  Google Scholar 

  38. Heimpel H (1995) Polycythemia vera: perspectives of future clinical trials. Onkologie 18: 512–516

    Google Scholar 

  39. Griesshammer M, Seifried E, Heimpel H (1993) Essentielle Thrombozythämie. Klinische Bedeutung, Diagnostik und Therapie. Dtsch Med Wochenschr 118: 1412–1417

    PubMed  CAS  Google Scholar 

  40. Schafer AI (1991) Essential thrombocythemia. Prog Hemost Thromb 10: 69–96

    PubMed  CAS  Google Scholar 

  41. Berk PD, Wasserman LR, Fruchtman SM, Goldberg JD (1995) Treatment of polycythemia vera: a summary of clinical trials conducted by the Polycythemia Vera Study Group. In: Wasserman LR, Berk PD, Berlin NI (eds) Polycythemia vera and the myeloproliferative disorders. Saunders, Philadelphia, pp 166–194

    Google Scholar 

  42. Barbui T (1994) Clinical epidemiology of thrombosis in 1213 patients with polycythemia vera (PV). Is a clinical trial of antithrombotic drugs feasible? Blood 84 [Suppl 1]: 57a

    Google Scholar 

  43. Anger B, Haug U, Seidler R, Heimpel H (1989) Polycythemia vera. A clinical study of 141 patients. Blut 59: 493–500

    PubMed  CAS  Google Scholar 

  44. Boivin P (1993) Indications, procedure and results for the treatment of polycythaemia vera by bleeding, pipobroman and hydroxyurea. Nouv Rev Fr Hematol 35: 491–498

    PubMed  CAS  Google Scholar 

  45. Messinezy M, Pearson TC, Prochazka A, Wetherley-Mein G (1985) Treatment of primary proliferative polycythaemia by venesection and low dose busulfan: retrospective study from one center. Br J Haematol 61: 657–666

    PubMed  CAS  Google Scholar 

  46. Arboix A, Besses C, Acin P et al (1995) Ischemic stroke as first manifestation of essential thrombocythemia. Report of six cases. Stroke 26: 1463–1466

    PubMed  CAS  Google Scholar 

  47. Chievitz E, Thiede T (1962) Complications and causes of death in polycythemia vera. Acta Med Scand 172: 513–523

    PubMed  CAS  Google Scholar 

  48. Fiessinger JN (1994) Thrombotic complications of polycythemia. The venous and arterial risk factors. Nouv Rev Fr Hematol 36: 179–181

    PubMed  CAS  Google Scholar 

  49. Muller EW, De Wolf JT, Haagsma EB (1993) Portal hypertension as presenting feature of a myeloproliferative disorder. Diagnosis and therapeutic dilemmas. Scand J Gastroenterol 200: 74–79

    CAS  Google Scholar 

  50. Pajor A, Lehoczky D (1993) Splenic thrombosis complicating pregnancy in patients with poor obstetrical outcome. A report of four cases. Ann Hematol 66: 319–321

    PubMed  CAS  Google Scholar 

  51. van Genderen PJ, Michiels JJ (1994) Erythromelalgic, thrombotic and haemorrhagic manifestations of thrombocythaemia. Presse Med 23: 73–77

    PubMed  Google Scholar 

  52. Budde U, Scharf RE, Franke P, Hartmann-Budde K, Dent J, Ruggeri ZM (1993) Elevated platelet count as a cause of abnormal von Willebrand factor multimer distribution in plasma. Blood 82: 1749-1757

    PubMed  CAS  Google Scholar 

  53. van Genderen PJ, Michiels JJ, van der Poel-van de Luytgaarde SC, van Vliet HH (1994) Acquired von Willebrand disease as a cause of recurrent mucocutaneous bleeding in primary thrombocythemia: relationship with platelet count. Ann Hematol 69: 81–84

    PubMed  Google Scholar 

  54. Pearson TC, Wetherley-Mein G (1978) Vascular occlusive episodes and venous hematocrit in primary proliferative polycythemia. Lancet ii: 1219–1222

    Google Scholar 

  55. Murphy S (1995) Megakaryocytes, platelets, and coagulation in the myeloproliferative disorders. In: Wasserman LR, Berk PD, Berlin NI (eds) Polycythemia vera and the myeloproliferative disorders. Saunders, Philadelphia, pp 102–113

    Google Scholar 

  56. Wehmeier A, Scharf RE, Fricke S, Schneider W (1990) A prospective study of hemostatic parameters in relation to the clinical course of myeloproliferative disorders. Eur J Hematol 45: 191–197

    CAS  Google Scholar 

  57. Baker RI, Manoharan A (1988) Platelet function in myeloproliferative disorders: characterization and sequential studies show multiple platelet abnormalities, and change with time. Eur J Haematol 40: 267–272

    PubMed  CAS  Google Scholar 

  58. Barbui T, Cortelazzo S, Viero P, Bassan R, Dini E, Semeraro N (1983) Thrombohemorrhagic complications in 101 cases of myeloproliferative disorders: relationship to platelet number and function. Eur J Cancer Clin Oncol 19: 1593–1599

    PubMed  CAS  Google Scholar 

  59. Randi ML, Fabris F, Girolami A (1990) Thrombocytosis in young people: evaluation of 57 cases diagnosed before the age of 40. Blut 60: 233–237

    PubMed  CAS  Google Scholar 

  60. Mitus AJ, Barbui T, Shulman LN et al (1990) Hemostatic complications in young patients with essential thrombocythemia. Am J Med 88: 371–375

    PubMed  CAS  Google Scholar 

  61. Millard FE, Hunter CS, Anderson M et al (1990) Clinical manifestations of essential thrombocythemia in young adults. Am J Hematol 33: 27–31

    PubMed  CAS  Google Scholar 

  62. McIntyre KJ, Hoagland HC, Silverstein MN, Petitt RM (1991) Essential thrombocythemia in young adults. Mayo Clin Proc 66: 149–154

    PubMed  CAS  Google Scholar 

  63. Frezzato M, Ruggeri M, Castaman G, Rodeghiero F (1993) Polycythemia vera and essential thrombocythemia in young patients. Haematologica 78 [Suppl 2]: 11–17

    PubMed  CAS  Google Scholar 

  64. Gordon MY, Atkinson J, Clarke D et al (1991) Deficiency of a phosphatidylinositol-anchored cell adhesion molecule influences haemopoietic progenitor binding to marrow stroma in chronic myeloid leukaemia. Leukemia 5: 693–698

    PubMed  CAS  Google Scholar 

  65. Verfaillie CM, McCarthy JB, McGlave PB (1992) Mechanisms underlying abnormal trafficking of malignant progenitors in chronic myelogenous leukemia. Decreased adhesion to stroma and fibronectin but increased adhesion to the basement membrane components laminin and collagen type IV. J Clin Invest 90: 1232–1241

    PubMed  CAS  Google Scholar 

  66. Eaves CJ, Cashman JD, Wolpe SD, Eaves AC (1993) Unresponsiveness of primitive chronic myeloid leukemia cells to macrophage inflammatory protein 1 alpha, an inhibitor of primitive normal hematopoietic cells. Proc Natl Acad Sci USA 90: 12015–12019

    PubMed  CAS  Google Scholar 

  67. Dowding C, Guo AP, Osterholz J, Siczkowski M, Goldman J, Gordon M (1991) Interferon-alpha overrides the deficient adhesion of chronic myeloid leukemia primitive progenitor cells to bone marrow stromal cells. Blood 78: 499–505

    PubMed  CAS  Google Scholar 

  68. Aman MJ, Keller U, Derigs G, Mohamadzadeh M, Huber C, Peschel C (1994) Regulation of cytokine expression by interferon-alpha in human bone marrow stromal cells: inhibition of hematopoietic growth factors and induction of interleukin-1 receptor antagonist. Blood 84: 4142–4150

    PubMed  CAS  Google Scholar 

  69. Muller EW, de Wolf JT, Hendriks DW, Esselink MT, Halie MR, Vellenga E (1993) Recombinant human mast cell growth factor supports erythroid colony formation in polycythemia vera in the presence and absence of erythropoietin and serum. Exp Hematol 21: 1353–1357

    PubMed  CAS  Google Scholar 

  70. Talpaz M, Mavligit G, Keating M, Walters RS, Gutterman JV (1983) Human leukocyte interferon to control thrombocytosis in chronic myelogenous leukemia. Ann Int Med 99: 789–792

    PubMed  CAS  Google Scholar 

  71. The Italian Cooperative Study Group on Chronic Myeloid Leukemia (1994) Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 330: 820–825

    Google Scholar 

  72. Zahner J, Wehmeier A, Schneider W (1995) Schwangerschaft bei essentieller Thrombozythämie. Manifestationszeitpunkt und Risiken für Mutter und Kind. Dtsch med Wschr 120: 1517–1523

    PubMed  CAS  Google Scholar 

  73. Williams JM, Schlesinger PE, Gray AG (1994) Successful treatment of essential thrombocythaemia and recurrent abortion with alpha interferon. Br J Haematol 88: 647–648

    PubMed  CAS  Google Scholar 

  74. Velu T, Delwiche F (1988) Treatment of essential thrombocythaemia by alpha-interferon. Lancet 2: 628

    PubMed  CAS  Google Scholar 

  75. Giles FJ, Singer CR, Gray AG et al (1988) Alpha-interferon therapy for essential thrombocythaemia. Lancet 2: 70–72

    PubMed  CAS  Google Scholar 

  76. Lazzarino M, Vitale A, Morra E et al (1989) Interferon alpha-2b as treatment for Philadelphia-negative chronic myeloproliferative disorders with excessive thrombocytosis. Br J Haematol 72: 173–177

    PubMed  CAS  Google Scholar 

  77. Bellucci S, Harousseau JL, Brice P, Tobelem G (1988) Treatment of essential thrombocythaemia by alpha 2a interferon. Lancet 2: 960–961

    PubMed  CAS  Google Scholar 

  78. Giles FJ (1991) Maintenance therapy in the myeloproliferative disorders: the current options. Br J Haematol 79 [Suppl 1]: 92–95

    PubMed  Google Scholar 

  79. Gisslinger H, Ludwig H, Linkesch W, Chott A, Fritz E, Radaszkiewicz T (1989) Long-term interferon therapy for thrombocytosis in myeloproliferative disorders. Lancet i: 634–637

    Google Scholar 

  80. Gisslinger H, Chott A, Scheithauer W, Gilly B, Linkesch W, Ludwig H (1991) Interferon in essential thrombocythaemia. Br J Haematol 79 [Suppl 1]: 42–47

    PubMed  Google Scholar 

  81. Seewann HL, Zikulnig R, Gallhofer G, Schmidt C (1991) Treatment of thrombocytosis in chronic myeloproliferative disorders with interferon alpha 2b. Eur J Cancer 27 [Suppl 4]: S58-S63

    PubMed  Google Scholar 

  82. Middelhoff G, Boll I (1992) A long-term clinical trial of interferon alpha-therapy in essential thrombocythemia. Ann Hematol 64: 207–209

    PubMed  CAS  Google Scholar 

  83. Sacchi S, Tabilio A, Leoni P et al (1993) Sustained complete hematological remission in essential thrombocythemia after discontinuation of long-term alpha-IFN treatment. Ann Hematol 66: 245–246

    PubMed  CAS  Google Scholar 

  84. Kasparu H, Bernhart M, Krieger O, Lutz D (1992) Remission may continue after termination of rIFN alpha-2b treatment for essential thrombocythemia. Eur J Haematol 48: 33–36

    PubMed  CAS  Google Scholar 

  85. Wehmeier A, Meierkord F, Schneider W (1994) Long-term therapy with interferon alpha in patients with essential thrombocythemia. Blood 84 [Suppl 1]: 58a

    Google Scholar 

  86. Linkesch W, Gisslinger H, Ludwig H, Flener R, Sinzinger H (1985) Therapie mit Interferon (rekombinantes IFN-α-2C) bei myeloproliferativen Erkrankungen mit exzessiven Thrombozytosen. Acta Med Austriaca 12: 123–127

    PubMed  CAS  Google Scholar 

  87. Taylor PC, Dolan G, Ng J-P, Paul B, Collin R, Reilly JT (1996) Efficacy of recombinant interferon-alpha (rIFN-α) in polycythemia vera: a study of 17 patients and an analysis of published data. Br J Haematol 92: 55–59

    PubMed  CAS  Google Scholar 

  88. Ariad S, Bezwoda WR (1991) Alpha-interferon for polycythemia vera. Blood 77: 670

    PubMed  CAS  Google Scholar 

  89. Cacciola E, Giustolisi R, Guglielmo P, Di Raimondo F, Cacciola E, Calogero RD (1991) Recombinant interferon alpha in the treatment of polycythemia vera. Blood 77: 2790–2791

    PubMed  CAS  Google Scholar 

  90. Turri D, Mitra ME, Di Trapani R, Lipari MG, Perricone R, Cajozzo A (1991) Alpha-interferon in polycythemia vera and essential thrombocythemia. Haematologica 76: 75–77

    PubMed  CAS  Google Scholar 

  91. de Wolf JT, Hendriks DW, Egger RC, Esselink MT, Halie MR, Vellenga E (1991) Alpha-interferon for intractable pruritus in polycythaemia vera. Lancet 337: 241

    PubMed  Google Scholar 

  92. Finelli C, Gugliotta L, Gamberi B, Vianelli N, Visani G, Tura S (1993) Relief of intractable pruritus in polycythemia vera with recombinant interferon alfa. Am J Hematol 43: 316–318

    PubMed  CAS  Google Scholar 

  93. Silver RT (1993) Interferon-alpha 2b: a new treatment for polycythemia vera. Ann Intern Med 119: 1091–1092

    PubMed  CAS  Google Scholar 

  94. Papineschi F, Bucalossi A, Capochiani E et al (1994) Recombinant alpha 2a interferon and polycythemia vera: clinical results and biological evaluation by means of Fourier-transform infrared microspectroscopy. Eur J Haematol 53: 213–217

    PubMed  CAS  Google Scholar 

  95. Castello G, Lerza R, Cerruti A, Cavallini D, Bogliolo G, Pannacciulli I (1994) The in vitro and in vivo effect of recombinant interferon alpha-2a on circulating haemopoietic progenitors in polycythaemia vera. Br J Haematol 87: 621–623

    PubMed  CAS  Google Scholar 

  96. Messora C, Bensi L, Vecchi A et al (1994) Cytogenetic conversion in a case of polycythaemia vera treated with interferon-alpha. Br J Haematol 86: 402–404

    PubMed  CAS  Google Scholar 

  97. Muller EW, de Wolf JT, Egger R et al (1995) Long-term treatment with interferon-alpha 2b for severe pruritus in patients with polycythaemia vera. Br J Haematol 89: 313–318

    PubMed  CAS  Google Scholar 

  98. Cimino R, Rametta V, Matera C, Mele G, Mettivier V, Ferrara F (1993) Recombinant interferon alpha- 2b in the treatment of polycythemia vera. Am J Hematol 44: 155–157

    PubMed  CAS  Google Scholar 

  99. Hansmann E, Bremer K (1994) Interferon-alpha in the polycythemia vera. Onkologie 17 [Suppl 2]: 53

    Google Scholar 

  100. Zahner J, Wehmeier A, Schneider W (1995) Alpha-interferon treatment in 12 patients with polycythemia vera. Onkologie 18 [Suppl 2]: 153

    Google Scholar 

  101. Sacchi S, Leoni P, Liberati M et al (1994) A prospective comparison between treatment with phlebotomy alone and with interferon-alpha in patients with polycythemia vera. Ann Hematol 68: 247–250

    PubMed  CAS  Google Scholar 

  102. Sacchi S, Tabilio A, Leoni P et al (1991) Interferon alpha-2b in the long-term treatment of essential thrombocythemia. Ann Hematol 63: 206–209

    PubMed  CAS  Google Scholar 

  103. Seewann HL (1993) Interferontherapie bei essentiellen Thrombozythämien. Wien Med Wochenschr 143: 420–424

    PubMed  CAS  Google Scholar 

  104. Gugliotta L, Bagnara GP, Catani L et al (1989) In vivo and in vitro inhibitory effect of alpha-interferon on megakaryocyte colony growth in essential thrombocythaemia. Br J Haematol 71: 177–181

    PubMed  CAS  Google Scholar 

  105. Chott A, Gisslinger H, Thiele J et al (1990) Interferon-alpha-induced morphological changes of megakaryocytes: a histomorphometrical study on bone marrow biopsies in chronic myeloproliferative disorders with excessive thrombocytosis. Br J Haematol 74: 10–16

    PubMed  CAS  Google Scholar 

  106. Franco V, Florena AM, Aragona F, Campesi G (1993) Morphometric study of the bone marrow in polycythemia vera following interferon-alpha therapy. Pathol Res Pract 189: 52–57

    PubMed  CAS  Google Scholar 

  107. Wadenvik H, Kutti J, Ridell B et al (1991) The effect of alpha-interferon on bone marrow megakaryocytes and platelet production rate in essential thrombocythemia. Blood 77: 2103–2108

    PubMed  CAS  Google Scholar 

  108. Marmont AM, Sessarego M (1995) Chronic clonal myeloproliferative disease associated with a t (5; 21) translocation. Complete but transient hematologic and cytogenetic remission induced by interferon-alpha. Leukemia 9: 977–9 80

    PubMed  CAS  Google Scholar 

  109. Hino M, Futami E, Okuno S, Miki T, Nishizawa Y, Morii H (1993) Possible selective effects of interferon alpha-2b on a malignant clone in a case of polycythemia vera. Ann Hematol 66: 161–162

    PubMed  CAS  Google Scholar 

  110. Najean Y, Rain JD, Toubert ME (1993) Treatment of polycythemia with 32P with or without hydroxyurea maintenance therapy. Preliminary results in 237 elderly and high vascular risk subjects studied since 1980. Presse Med 22: 1951–1956

    PubMed  CAS  Google Scholar 

  111. Brandt L, Anderson H (1995) Survival and risk of leukaemia in polycythaemia vera and essential thrombocythaemia treated with oral radiophosphorus: are safer drugs available? Eur J Haematol 54: 21–26

    PubMed  CAS  Google Scholar 

  112. Chistolini A, Mazzucconi MG, Ferrari A et al (1990) Essential thrombocythemia: a retrospective study on the clinical course of 100 patients. Haematologica 75: 537–540

    PubMed  CAS  Google Scholar 

  113. Rain JD (1994) Clinical and laboratory assessment and therapeutic problems in longstanding polycythaemia vera. Nouv Rev Fr Hematol 36: 197–203

    PubMed  CAS  Google Scholar 

  114. Spadea A, Petti HC, Spiriti HAA et al (1994) Pipobroman in polycythemia vera patients: a retrospective analysis. Blood 84 [Suppl 1]: 58a

    Google Scholar 

  115. Andres WA, Novak RJ, Fleming JS (1984) Inhibition of platelet production induced by an antiplatelet drug, anagrelide, in normal volunteers. Thromb Haemost 52: 325–328

    Google Scholar 

  116. Spencer CM, Brogden RN (1994) Anagrelide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of thrombocythaemia. Drugs 47: 809–822

    PubMed  CAS  Google Scholar 

  117. Mazzucconi MG, De Sanctis V, Chistolini A, Dragoni F, Mandelli F (1992) Therapy with anagrelide in patients affected by essential thrombocythemia: preliminary results. Haematologica 77: 315–317

    PubMed  CAS  Google Scholar 

  118. Anagrelide Study Group (1992) Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Am J Med 92: 69–76

    Google Scholar 

  119. Ludwig H, Linkesch W, Gisslinger H et al (1987) Interferon alfa corrects thrombocytosis in patients with myeloproliferative disorders. Cancer Immunol Immunother 25: 266–273

    PubMed  CAS  Google Scholar 

  120. May D, Wandl UB, Niederle N (1989) Treatment of essential thrombocythaemia with interferon alpha-2b. Lancet 1: 96

    PubMed  CAS  Google Scholar 

  121. Talpaz M, Kurzrock R, Kantarjian H, O’Brien S, Gutterman JU (1989) Recombinant interferon-alpha therapy of Philadelphia chromosome-negative myeloproliferative disorders with thrombocytosis. Am J Med 86: 554–558

    PubMed  CAS  Google Scholar 

  122. Abegg-Werter MJ, Raemackers JM, de Pauw BE, Haanen C (1990) Recombinant interferon-alpha, but not interferon-gamma is effective therapy for essential thrombocythemia. Blut 60: 37–40

    PubMed  CAS  Google Scholar 

  123. Giralt M, Rubio D, Cortes MT et al (1991 Alpha Interferon in the management of essential thrombocythaemia. Eur J Cancer 27: S72–74

    PubMed  Google Scholar 

  124. Yataganas X, Meletis J, Plata E et al (1991) Alpha Interferon treatment of essential thrombocythaemia and other myeloproliferative disorders with excessive thrombocytosis. Eur J Cancer 27: S69–71

    PubMed  Google Scholar 

  125. Rametta V, Ferrara F, Marottoli V, Matera C, Mettivier V, Cimino R (1994) Recombinant interferon alpha-2b as treatment of essential thrombocythaemia. Acta Haematol 91: 126–129

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. A. Wehmeier
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Heinrich-Heine-Universität Düsseldorf, Moorenstraße 5, 40225, Düsseldorf, Germany

    Carlo Aul  & Wolfgang Schneider  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1997 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Wehmeier, A. (1997). Interferon Therapy of Essential Thrombocythemia and Polycythemia Vera. In: Aul, C., Schneider, W. (eds) Interferons. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-60411-9_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-60411-9_6

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-61051-9

  • Online ISBN: 978-3-642-60411-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation